COUP-TFII regulates tumor growth and metastasis by modulating tumor angiogenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 8, 2010, Pages 3687-3692

  Qin, Jun ^a   Chen, Xinpu ^a   Xie, Xin ^a   Tsai, Ming Jer ^a   Tsai, Sophia Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Angiopoietin 1 Tie2; Tumor progression and metastasis

Indexed keywords

ANGIOPOIETIN 1; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; METASTASIS; MICROENVIRONMENT; MODULATION; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; XENOGRAFT;

ANGIOPOIETIN-1; ANIMALS; COUP TRANSCRIPTION FACTOR II; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649252156     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914619107     Document Type: Article

References (33)

1. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
2. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478.
3. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
4. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049.
5. Suri C, et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180.
6. Jones N, Iljin K, Dumont DJ, Alitalo K (2001) Tie receptors: New modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2:257-267.
7. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676.
8. Dickson MC, et al. (1995) Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121:1845-1854.
9. Larsson J, et al. (2001) Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J 20:1663-1673.
10. Hamada K, et al. (2005) The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19:2054-2065.
11. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681-691.
12. Yancopoulos GD, et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
13. Lindblom P, et al. (2003) Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17:1835-1840.
14. Tsai SY, Tsai MJ (1997) Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): Coming of age. Endocr Rev 18:229-240.
15. Qin J, Tsai MJ, Tsai SY (2008) Essential roles of COUP-TFII in Leydig cell differentiation and male fertility. PLoS One 3:e3285.
16. You LR, et al. (2005) Mouse lacking COUP-TFII as an animal model of Bochdalek-type congenital diaphragmatic hernia. Proc Natl Acad Sci USA 102:16351-16356.
17. You LR, et al. (2005) Suppression of Notch signaling by the COUP-TFII transcription factor regulates vein identity. Nature 435:98-104.
18. Takamoto N, et al. (2005) COUP-TFII is essential for radial and anteroposterior patterning of the stomach. Development 132:2179-2189.
19. Pereira FA, Qiu Y, Zhou G, Tsai MJ, Tsai SY (1999) The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes Dev 13:1037-1049.
20. de Luca C, et al. (2005) Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest 115:3484-3493.
21. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12:954-961.
22. Shim WS, Ho IA, Wong PE (2007) Angiopoietin: A TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5:655-665.
23. Maisonpierre PC, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60.
24. Pipaón C, Tsai SY, Tsai MJ (1999) COUP-TF upregulates NGFI-A gene expression through an Sp1 binding site. Mol Cell Biol 19:2734-2745.
25. Kim BJ, Takamoto N, Yan J, Tsai SY, Tsai MJ (2009) Chicken Ovalbumin Upstream Promoter-Transcription Factor II (COUP-TFII) regulates growth and patterning of the postnatal mouse cerebellum. Dev Biol 326:378-391.
26. Rohr O, Aunis D, Schaeffer E (1997) COUP-TF and Sp1 interact and cooperate in the transcriptional activation of the human immunodeficiency virus type 1 long terminal repeat in human microglial cells. J Biol Chem 272:31149-31155.
27. Kruse SW, et al. (2008) Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. PLoS Biol 6:e227.
28. Gurevich F, Perazella MA (2009) Renal effects of anti-angiogenesis therapy: Update for the internist. Am J Med 122:322-328.
29. Uemura A, et al. (2002) Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 110: 1619-1628.
30. Thurston G, et al. (2005) Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 132:3317-3326.
31. Stoeltzing O, et al. (2003) Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63:3370-3377.
32. Shim WS, et al. (2002) Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 279:299-309.
33. Gale NW, et al. (2002) Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3: 411-423.